Product Information
TRELEGY ELLIPTA 200-62.5-25 is a brand product labeled by GlaxoSmithKline LLC, priced at $11.1997 per EA under NDC 00173089314. Its NADAC has been published 294 times since Feb 17, 2021.
FDA first approved this application on Sep 18, 2017.
TRELEGY ELLIPTA 200-62.5-25
fluticasone furoate, umeclidinium bromide and vilanterol trifenatateStrength
200; 62.5; 25 ug/1; ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173089314
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA209482FDA Approved
9/18/2017
On Market Since
9/9/2020
Pharmacological Classes
Price Statistics
The NADAC for TRELEGY ELLIPTA 200-62.5-25 has been published 294 times since Feb 17, 2021, and over the history we have for it it has risen 16.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.1997 per EA |
|---|---|
| All-time high | $11.2215 (Jul 15, 2026) |
| All-time low | $9.5641 (Apr 21, 2021) |
| 52-week high | $11.2215 |
| 52-week low | $10.8535 |
| Median price | $10.1465 |
| Average price | $10.3309 |
| Largest weekly change | +3.0% (Jan 8, 2025) |
| Weeks tracked | 294 |
| Tracking since | Feb 17, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone furoate, umeclidinium bromide and vilanterol trifenatate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRELEGY ELLIPTA 200-62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for TRELEGY ELLIPTA 200-62.5-25, manufactured by GlaxoSmithKline LLC, is $11.1997 per EA (NDC 00173089314), effective Sep 30, 2026.
How has the price of TRELEGY ELLIPTA 200-62.5-25 changed over time?
Over the history we have for it, the NADAC for TRELEGY ELLIPTA 200-62.5-25 has risen 16.4%. It has been tracked across 294 weekly CMS publications since Feb 17, 2021.
What are the highest and lowest recorded NADAC prices for TRELEGY ELLIPTA 200-62.5-25?
Since Feb 17, 2021, the NADAC for TRELEGY ELLIPTA 200-62.5-25 has ranged from a low of $9.5641 (Apr 21, 2021) to a high of $11.2215 (Jul 15, 2026), with a median of $10.1465 per EA.
Are there cheaper alternatives to TRELEGY ELLIPTA 200-62.5-25?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRELEGY ELLIPTA 200-62.5-25, is $11.1525 per EA — about 0% below TRELEGY ELLIPTA 200-62.5-25.
Who manufactures TRELEGY ELLIPTA 200-62.5-25?
TRELEGY ELLIPTA 200-62.5-25 (NDC 00173089314) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.